Lab to Market Leadership with Chris Reichhelm

With over 25 years of experience in recruiting leadership teams and boards for advanced science and engineering companies, Chris Reichhelm, CEO of Deep Tech Leaders, offers an insider’s perspective on the pivotal decisions and strategies that shape the success of startups embarking on the lab-to-market journey.

This podcast doesn’t just celebrate innovation for its own sake; instead, it highlights what it truly takes to build, scale, and sustain a successful deep tech company. Through conversations with entrepreneurs, investors, executives, and other key players, Chris will explore the management disciplines, cultures, and behaviours essential for commercialising and scaling deep tech innovations. Each episode will aim to unravel the complexities behind turning rich, research-intensive IP into commercially viable products across various sectors like computing, biotech, materials science, and more.

'Lab to Market Leadership' is for those who are ready to learn from past mistakes and successes to better navigate the path from innovation to market. Whether you're an entrepreneur, an investor, or simply a deep tech enthusiast, this podcast offers valuable lessons and insights to enhance your understanding and approach to building groundbreaking companies that aim to solve the world's biggest problems and improve our way of life.

Learn more about Lab to Market Leadership: www.deeptechleaders.com

Follow us on LinkedIn: www.linkedin.com/company/deeptechleaders

Podcast Production by Beauxhaus

Guest

Eric Mayes PhD

Eric Mayes is the CEO of Endomag, a company that spun out from University College London and the University of Houston in 2010. Under Eric's leadership, Endomag developed innovative solutions in the healthcare sector, culminating in a significant acquisition by Hologic for $310 million last year. Eric is a unique figure in the UK startup scene, bringing a wealth of experience from founding two advanced materials companies, Nanomagnetics and Apoclara, as well as contributing to the growth of Cambridge Display Technologies, one of the first Cambridge spin-outs to float on NASDAQ. His extensive background and strategic vision have been key to Endomag’s success, making this episode a special opportunity to hear from a CEO who has navigated the startup journey from inception to exit.

https://www.linkedin.com/in/emayes/

Guest appearance on:

Lab to £30m+ in revenue and a $310m exit | Eric Mayes | CEO of Endomag